LncRNA MKLN1-AS promotes glioma tumorigenesis and growth via activating the Hippo pathway through miR-126-5p/TEAD1 axis
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-024-03646-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Shouren Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, 59 Shengli West Road, Zhangzhou, Fujian, 363000, P.R. China. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, RNA, Long Noncoding, TEA Domain Transcription Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Climbing Project of Zhangzhou Hospital Doctor Studio.
Abstract (Originalsprache)
The involvement of long non-coding RNAs (lncRNAs) in glioma carcinogenesis has gradually been identified. Herein, we aimed to explore the function and mechanism of lncRNA muskelin 1 antisense RNA (MKLN1-AS) in glioma cell oncogenic properties. Quantitative real-time polymerase chain reaction was utilized to test the expression of MKLN1-AS, miR-126-5p, and TEAD1 (TEA Domain Transcription Factor 1) mRNA expression. Oncogenic properties of glioma cells were characterized using 5-ethynyl-2'-deoxyuridine, flow cytometry, wound healing, transwell, and tube formation assays, respectively. Levels of TEAD1 protein, mobility-related proteins, and Hippo pathway-related proteins were examined by Western blotting. The binding between miR-126-5p and MKLN1-AS or TEAD1 was confirmed by using dual-luciferase reporter and pull-down assays. The murine xenograft model was established for in vivo analysis. Levels of MKLN1-AS in glioma tissues and cell lines were higher, functionally, MKLN1-AS deficiency could suppress glioma cell proliferation, migration, invasion, and angiogenesis, and induce apoptosis in vitro, as well as impede tumor growth in vivo. Mechanistically, miR-126-5p was targeted by MKLN1-AS, miR-126-5p directly targeted TEAD1. The suppressing effects of MKLN1-AS deficiency on glioma cell oncogenic properties were abolished by TEAD1 overexpression or miR-126-5p inhibition. Besides, MKLN1-AS/miR-126-5p mediates the activation of Hippo pathway by TEAD1. MKLN1-AS knockdown weakened glioma cell oncogenic phenotypes and growth via TEAD1-Hippo pathway through miR-126-5p, indicating a new therapeutic target for glioma molecular therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, 59 Shengli West Road, Zhangzhou, Fujian, 363000, P.R. China.
- Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, 59 Shengli West Road, Zhangzhou, Fujian, 363000, P.R. China. csr202306@163.com.
Förderung
- Climbing Project of Zhangzhou Hospital Doctor Studio
Zitieren
APA
Chen, S., Tu, S., Huang, Y., Lin, H., Wang, Y., & Dai, X. (2025). LncRNA MKLN1-AS promotes glioma tumorigenesis and growth via activating the Hippo pathway through miR-126-5p/TEAD1 axis. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03646-y
Vancouver
Chen S, Tu S, Huang Y, Lin H, Wang Y, Dai X. LncRNA MKLN1-AS promotes glioma tumorigenesis and growth via activating the Hippo pathway through miR-126-5p/TEAD1 axis. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03646-y
BibTeX
@article{Chen2025,
author = {Chen, Shouren and Tu, Songjie and Huang, Yan and Lin, Hong and Wang, Yuzhe and Dai, Xuejun},
title = {LncRNA MKLN1-AS promotes glioma tumorigenesis and growth via activating the Hippo pathway through miR-126-5p/TEAD1 axis},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-024-03646-y}
}
EUVIMED